Genmab — Maj 2015
-
3 sCR , 10 VGPR
-
Time to progression er dog lav med kun 3,7 måneder.
-
Det er dog også virkelig virkelig pretreatet patienter. Prior lines of therapi er over 5 !
-
63% har fået pomalyst og 48% kyprolis inden dara
-
virkelig flot safety profil også
-
Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients
/PRNewswire/ -- Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent...
(www.prnewswire.com)
-
ved vi om data har taget højde for det nye m-komponent assay ?
-
eller om nogle VGPR kan blive CR hvis man målte med dette ?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind